Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta‐Analysis

The aim of this work was to utilize meta‐analysis in examining the effects of memantine on neuropsychological functioning in patients with Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB).

[1]  N. Iwata,et al.  Memantine for Lewy body disorders: systematic review and meta-analysis. , 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[2]  E. Londos,et al.  Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies , 2015, International journal of geriatric psychiatry.

[3]  E. Londos,et al.  Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study , 2014, BMJ Open.

[4]  L. Tan,et al.  Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  R. Barker,et al.  Health‐related quality of life in early Parkinson's disease: The impact of nonmotor symptoms , 2014, Movement disorders : official journal of the Movement Disorder Society.

[6]  K. Dujardin,et al.  The spectrum of cognitive disorders in Parkinson's disease: A data‐driven approach , 2013, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Dixon,et al.  Neurocognitive Speed and Inconsistency in Parkinson's Disease with and without Incipient Dementia: An 18-Month Prospective Cohort Study , 2012, Journal of the International Neuropsychological Society.

[8]  I. Maidment,et al.  Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. , 2012, The Cochrane database of systematic reviews.

[9]  C. Wattmo,et al.  Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson’s Disease Dementia , 2011, Dementia and Geriatric Cognitive Disorders.

[10]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[11]  Regina Katzenschlager,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[12]  W. Ondo,et al.  Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. , 2011, Parkinsonism & related disorders.

[13]  Angie A. Kehagia,et al.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.

[14]  Roy W Jones,et al.  Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[15]  E. Londos,et al.  The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia , 2010, International journal of geriatric psychiatry.

[16]  Johannes C. Klein,et al.  Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.

[17]  D. Aarsland,et al.  The epidemiology of dementia associated with Parkinson disease , 2010, Journal of the Neurological Sciences.

[18]  I. Litvinenko,et al.  Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia , 2010, Neuroscience and Behavioral Physiology.

[19]  S. MacDonald,et al.  Neural underpinnings of within-person variability in cognitive functioning. , 2009, Psychology and aging.

[20]  E. Londos,et al.  Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial , 2009, The Lancet Neurology.

[21]  A. Burns,et al.  Randomized controlled trial of memantine in dementia associated with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[22]  M. Fava,et al.  Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report , 2009, Psychological Medicine.

[23]  Dag Aarsland,et al.  Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria , 2008, Dementia and Geriatric Cognitive Disorders.

[24]  T. Babić,et al.  Is quality of life in non‐demented Parkinson’s disease patients related to cognitive performance? A clinic‐based cross‐sectional study , 2008, European journal of neurology.

[25]  Cindy M. de Frias,et al.  Intraindividual variability in neurocognitive speed: A comparison of Parkinson's disease and normal older adults , 2007, Neuropsychologia.

[26]  E. Tolosa,et al.  Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[28]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[29]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[30]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[31]  I Ferrer,et al.  Abnormal Metabotropic Glutamate Receptor Expression and Signaling in the Cerebral Cortex in Diffuse Lewy Body Disease is Associated with Irregular α‐Synuclein/Phospholipase C (PLCβ1) Interactions , 2004, Brain pathology.

[32]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[33]  G. N. Kryzhanovskiĭ,et al.  Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats , 2000, Bulletin of Experimental Biology and Medicine.

[34]  L. Thal,et al.  Cholinergic dysfunction in diseases with Lewy bodies , 2000, Neurology.

[35]  M. Yamada,et al.  [Dementia rating scale]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[36]  M. Starr.  Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease , 1995, Synapse.

[37]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[38]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[39]  K. Shapovalova,et al.  Comparison of the Effects of Systemic (intramuscular) and Intrastriatal Administration of a Selective D1 Dopamine Receptor Blocker on Motor Behavior and Postural Rearrangement in Dogs , 2009, Neuroscience and Behavioral Physiology.

[40]  O. Levin,et al.  Efficacy and safety of memantine in Lewy body dementia , 2009, Neuroscience and Behavioral Physiology.